

### USA, NPCR, Native American (1998-2012)

	Number of cases							Percentage				Incidence rates per million person-years								MV % 0-19	DCO % 0-19	
	0	1-4	Age group			0-14	0-19	All	0-14		All	Group	Age-specific					Cumulative				
			5-9	10-14	15-19				0-14	0-19			0	1-4	5-9	10-14	15-19	0-14	0-19			0-14
<b>I LEUKAEMIA</b>	31	176	99	78	104	<b>384</b>	<b>488</b>	34.8	100.0	29.3	100.0	34.9	50.6	22.5	16.9	22.2	<b>30.5</b>	<b>28.7</b>	434	545	97.5	1.2
a. Lymphoid	12	148	76	41	52	<b>277</b>	<b>329</b>	25.1	72.1	19.7	67.4	13.5	42.5	17.3	8.9	11.1	<b>22.3</b>	<b>19.8</b>	314	370	98.5	0.9
b. Acute myeloid	9	20	15	29	33	<b>73</b>	<b>106</b>	6.6	19.0	6.4	21.7	10.1	5.7	3.4	6.3	7.1	<b>5.5</b>	<b>5.8</b>	82	117	99.1	0.9
c. CMD	1	1	1	5	9	<b>8</b>	<b>17</b>	0.7	2.1	1.0	3.5	1.1	0.3	0.2	1.1	1.9	<b>0.6</b>	<b>0.9</b>	9	18	82.4	0.0
d. MDS & other	8	4	4	2	4	<b>18</b>	<b>22</b>	1.6	4.7	1.3	4.5	9.0	1.1	0.9	0.4	0.9	<b>1.5</b>	<b>1.3</b>	20	25	100.0	0.0
e. Unspecified	1	3	3	1	6	<b>8</b>	<b>14</b>	0.7	2.1	0.8	2.9	1.1	0.9	0.7	0.2	1.3	<b>0.6</b>	<b>0.8</b>	9	15	78.6	14.3
<b>II LYMPHOMA &amp; RELATED</b>	6	31	24	48	76	<b>109</b>	<b>185</b>	9.9	100.0	11.1	100.0	6.8	8.9	5.5	10.4	16.3	<b>8.1</b>	<b>9.9</b>	122	203	98.4	0.5
a. Hodgkin	0	3	3	13	47	<b>19</b>	<b>66</b>	1.7	17.4	4.0	35.7	-	0.9	0.7	2.8	10.1	<b>1.3</b>	<b>3.3</b>	21	71	100.0	0.0
b. Non-Hodgkin except BL	0	7	12	26	22	<b>45</b>	<b>67</b>	4.1	41.3	4.0	36.2	-	2.0	2.7	5.6	4.7	<b>3.1</b>	<b>3.5</b>	50	73	95.5	1.5
c. Burkitt (BL)	0	4	4	7	5	<b>15</b>	<b>20</b>	1.4	13.8	1.2	10.8	-	1.1	0.9	1.5	1.1	<b>1.1</b>	<b>1.1</b>	17	22	100.0	0.0
d. Lymphoreticular	5	17	5	2	1	<b>29</b>	<b>30</b>	2.6	26.6	1.8	16.2	5.6	4.9	1.1	0.4	0.2	<b>2.4</b>	<b>1.9</b>	33	34	100.0	0.0
e. Unspecified	1	0	0	0	1	<b>1</b>	<b>2</b>	0.1	0.9	0.1	1.1	1.1	-	-	-	0.2	<b>0.1</b>	<b>0.1</b>	1	2	100.0	0.0
<b>III CNS NEOPLASMS †</b>	15	69	84	84	114	<b>252</b>	<b>366</b>	22.8	100.0	21.9	100.0	16.9	19.8	19.1	18.2	24.4	<b>18.9</b>	<b>20.1</b>	283	405	77.3	0.8
a. Ependymoma	4	13	5	4	7	<b>26</b>	<b>33</b>	2.4	10.3	2.0	9.0	4.5	3.7	1.1	0.9	1.5	<b>2.1</b>	<b>2.0</b>	29	37	97.0	3.0
b. Astrocytoma	6	26	32	29	26	<b>93</b>	<b>119</b>	8.4	36.9	7.1	32.5	6.8	7.5	7.3	6.3	5.6	<b>7.0</b>	<b>6.7</b>	104	132	89.9	0.0
c. CNS embryonal	4	14	19	8	11	<b>45</b>	<b>56</b>	4.1	17.9	3.4	15.3	4.5	4.0	4.3	1.7	2.4	<b>3.5</b>	<b>3.2</b>	51	63	98.2	1.8
d. Other gliomas	0	10	15	13	10	<b>38</b>	<b>48</b>	3.4	15.1	2.9	13.1	-	2.9	3.4	2.8	2.1	<b>2.8</b>	<b>2.7</b>	43	53	43.8	0.0
e. Other specified	1	3	11	27	52	<b>42</b>	<b>94</b>	3.8	16.7	5.6	25.7	1.1	0.9	2.5	5.9	11.1	<b>2.9</b>	<b>4.7</b>	46	102	61.7	0.0
f. Unspecified CNS	0	3	2	3	8	<b>8</b>	<b>16</b>	0.7	3.2	1.0	4.4	-	0.9	0.5	0.7	1.7	<b>0.6</b>	<b>0.9</b>	9	18	62.5	6.3
<b>IV NEUROBLASTOMA</b>	23	34	5	1	2	<b>63</b>	<b>65</b>	5.7	100.0	3.9	100.0	25.9	9.8	1.1	0.2	0.4	<b>5.5</b>	<b>4.3</b>	72	74	100.0	0.0
a. (Ganglio)neuroblastoma	23	34	5	1	0	<b>63</b>	<b>63</b>	5.7	100.0	3.8	96.9	25.9	9.8	1.1	0.2	-	<b>5.5</b>	<b>4.2</b>	72	72	100.0	0.0
b. Peripheral nervous	0	0	0	0	2	<b>0</b>	<b>2</b>	-	-	0.1	3.1	-	-	-	-	0.4	-	<b>0.1</b>	-	2	100.0	0.0
<b>V RETINOBLASTOMA</b>	8	11	2	0	1	<b>21</b>	<b>22</b>	1.9	100.0	1.3	100.0	9.0	3.2	0.5	-	0.2	<b>1.8</b>	<b>1.5</b>	24	25	77.3	4.5
<b>VI RENAL TUMOURS</b>	8	39	7	2	5	<b>56</b>	<b>61</b>	5.1	100.0	3.7	100.0	9.0	11.2	1.6	0.4	1.1	<b>4.8</b>	<b>4.0</b>	64	69	98.4	0.0
a. Nephroblastoma	8	39	5	0	1	<b>52</b>	<b>53</b>	4.7	92.9	3.2	86.9	9.0	11.2	1.1	-	0.2	<b>4.5</b>	<b>3.6</b>	59	61	100.0	0.0
b. Renal carcinoma	0	0	2	2	4	<b>4</b>	<b>8</b>	0.4	7.1	0.5	13.1	-	-	0.5	0.4	0.9	<b>0.3</b>	<b>0.4</b>	4	9	87.5	0.0
c. Unspecified	0	0	0	0	0	<b>0</b>	<b>0</b>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>VII HEPATIC TUMOURS</b>	6	15	3	2	3	<b>26</b>	<b>29</b>	2.4	100.0	1.7	100.0	6.8	4.3	0.7	0.4	0.6	<b>2.2</b>	<b>1.9</b>	30	33	100.0	0.0
a. Hepatoblastoma	6	14	3	0	0	<b>23</b>	<b>23</b>	2.1	88.5	1.4	79.3	6.8	4.0	0.7	-	-	<b>2.0</b>	<b>1.5</b>	26	26	100.0	0.0
b. Hepatic carcinoma	0	1	0	2	3	<b>3</b>	<b>6</b>	0.3	11.5	0.4	20.7	-	0.3	-	0.4	0.6	<b>0.2</b>	<b>0.3</b>	3	7	100.0	0.0
c. Unspecified	0	0	0	0	0	<b>0</b>	<b>0</b>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
<b>VIII BONE TUMOURS</b>	0	3	17	33	41	<b>53</b>	<b>94</b>	4.8	100.0	5.6	100.0	-	0.9	3.9	7.2	8.8	<b>3.6</b>	<b>4.8</b>	59	102	95.7	2.1
a. Osteosarcoma	0	0	11	21	26	<b>32</b>	<b>58</b>	2.9	60.4	3.5	61.7	-	-	2.5	4.6	5.6	<b>2.1</b>	<b>2.9</b>	35	63	98.3	0.0
b. Chondrosarcoma	0	0	1	0	2	<b>1</b>	<b>3</b>	0.1	1.9	0.2	3.2	-	-	0.2	-	0.4	<b>0.1</b>	<b>0.2</b>	1	3	100.0	0.0
c. Ewing & related	0	3	4	10	9	<b>17</b>	<b>26</b>	1.5	32.1	1.6	27.7	-	0.9	0.9	2.2	1.9	<b>1.2</b>	<b>1.4</b>	19	28	96.2	3.8
d. Other specified	0	0	1	1	1	<b>2</b>	<b>3</b>	0.2	3.8	0.2	3.2	-	-	0.2	0.2	0.2	<b>0.1</b>	<b>0.2</b>	2	3	100.0	0.0
e. Unspecified	0	0	0	1	3	<b>1</b>	<b>4</b>	0.1	1.9	0.2	4.3	-	-	-	0.2	0.6	<b>0.1</b>	<b>0.2</b>	1	4	50.0	25.0
<b>IX SOFT TISSUE SARCOMA</b>	6	26	12	23	40	<b>67</b>	<b>107</b>	6.1	100.0	6.4	100.0	6.8	7.5	2.7	5.0	8.6	<b>5.2</b>	<b>5.9</b>	75	118	100.0	0.0
a. Rhabdomyosarcoma	1	19	3	7	7	<b>30</b>	<b>37</b>	2.7	44.8	2.2	34.6	1.1	5.5	0.7	1.5	1.5	<b>2.4</b>	<b>2.2</b>	34	41	100.0	0.0
b. Fibrosarcoma	4	0	2	1	2	<b>7</b>	<b>9</b>	0.6	10.4	0.5	8.4	4.5	-	0.5	0.2	0.4	<b>0.6</b>	<b>0.5</b>	8	10	100.0	0.0
c. Kaposi sarcoma	0	0	0	0	0	<b>0</b>	<b>0</b>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
d. Other specified	1	6	6	13	27	<b>26</b>	<b>53</b>	2.4	38.8	3.2	49.5	1.1	1.7	1.4	2.8	5.8	<b>1.9</b>	<b>2.8</b>	29	58	100.0	0.0
e. Unspecified	0	1	1	2	4	<b>4</b>	<b>8</b>	0.4	6.0	0.5	7.5	-	0.3	0.2	0.4	0.9	<b>0.3</b>	<b>0.4</b>	4	9	100.0	0.0
<b>X GERM CELL TUMOURS</b>	8	5	4	16	66	<b>33</b>	<b>99</b>	3.0	100.0	5.9	100.0	9.0	1.4	0.9	3.5	14.1	<b>2.5</b>	<b>5.1</b>	37	107	98.0	0.0
a. CNS germ cell	2	1	1	8	3	<b>12</b>	<b>15</b>	1.1	36.4	0.9	15.2	2.3	0.3	0.2	1.7	0.6	<b>0.8</b>	<b>0.8</b>	13	16	93.3	0.0
b. Other extragonadal	4	1	2	0	9	<b>7</b>	<b>16</b>	0.6	21.2	1.0	16.2	4.5	0.3	0.5	-	1.9	<b>0.6</b>	<b>0.9</b>	8	18	93.8	0.0
c. Gonadal germ cell	2	3	1	7	52	<b>13</b>	<b>65</b>	1.2	39.4	3.9	65.7	2.3	0.9	0.2	1.5	11.1	<b>1.0</b>	<b>3.2</b>	14	70	100.0	0.0
d. Gonadal carcinoma	0	0	0	0	1	<b>0</b>	<b>1</b>	-	-	0.1	1.0	-	-	-	-	0.2	-	<b>0.0</b>	-	1	100.0	0.0
e. Unspecified gonadal	0	0	0	1	1	<b>1</b>	<b>2</b>	0.1	3.0	0.1	2.0	-	-	-	0.2	0.2	<b>0.1</b>	<b>0.1</b>	1	2	100.0	0.0
<b>XI CARCINOMA &amp; MELANOMA</b>	1	4	7	24	107	<b>36</b>	<b>143</b>	3.3	100.0	8.6	100.0	1.1	1.1	1.6	5.2	22.9	<b>2.5</b>	<b>7.1</b>	40	154	100.0	0.0
a. Adrenocortical	1	3	1	0	0	<b>5</b>	<b>5</b>	0.5	13.9	0.3	3.5	1.1	0.9	0.2	-	-	<b>0.4</b>	<b>0.3</b>	6	6	100.0	0.0
b. Thyroid	0	1	2	10	44	<b>13</b>	<b>57</b>	1.2	36.1	3.4	39.9	-	0.3	0.5	2.2	9.4	<b>0.9</b>	<b>2.8</b>	14	61	100.0	0.0
c. Nasopharyngeal	0	0	0	3	8	<b>3</b>	<b>11</b>	0.3	8.3	0.7	7.7	-	-	-	0.7	1.7	<b>0.2</b>	<b>0.5</b>	3	12	100.0	0.0
d. Melanoma	0	0	3	5	10	<b>8</b>	<b>18</b>	0.7	22.2	1.1	12.6	-	-	0.7	1.1	2.1	<b>0.5</b>	<b>0.9</b>	9	20	100.0	0.0
e. Skin carcinoma	0	0	0	0	0	<b>0</b>	<b>0</b>	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
f. Other & unspecified	0	0	1	6	45	<b>7</b>	<b>52</b>	0.6	19.4	3.1	36.4	-	-	0.2	1.3	9.6	<b>0.5</b>	<b>2.5</b>	8	56	100.0	0.0
<b>XII OTHER &amp; UNSPECIFIED</b>	3	1	0	1	4	<b>5</b>	<b>9</b>	0.5	100.0	0.5	100.0	3.4	0.3	-	0.2	0.9	<b>0.4</b>	<b>0.5</b>	6	10	77.8	11.1
a. Other specified	2	1	0	0	1	<b>3</b>	<b>4</b>	0.3	60.0	0.2	44.4	2.3	0.3	-	-	0.2	<b>0.3</b>	<b>0.3</b>	3	5	100.0	0.0
b. Other unspecified	1	0	0	1	3	<b>2</b>	<b>5</b>	0.2	40.0	0.3	55.6	1.1	-	-	0.2	0.6	<b>0.2</b>	<b>0.3</b>				

## USA, NPCR, Native American (1998-2012)

	Males										M/F ratio		Females									
	Number of cases in age groups					ASR per million							Number of cases in age groups					ASR per million				
	0	1-4	5-9	10-14	15-19	0-14	0-19	0-14	0-19	0-14	0-19	0	1-4	5-9	10-14	15-19	0-14	0-19	0-14	0-19		
<b>I LEUKAEMIA</b>	16	102	56	35	61	209	270	33.0	31.3	1.2	1.2	15	74	43	43	43	175	218	27.9	25.9		
a. Lymphoid	5	86	43	22	38	156	194	24.8	22.8	1.3	1.4	7	62	33	19	14	121	135	19.8	16.7		
b. Acute myeloid	5	12	9	9	15	35	50	5.4	5.6	0.9	0.9	4	8	6	20	18	38	56	5.6	6.1		
c. CMD	0	1	0	3	4	4	8	0.5	0.8	1.0	0.9	1	0	1	2	5	4	9	0.6	0.9		
d. MDS & other	5	2	2	0	1	9	10	1.5	1.3	1.0	0.8	3	2	2	2	3	9	12	1.5	1.4		
e. Unspecified	1	1	2	1	3	5	8	0.8	0.9	1.7	1.3	0	2	1	0	3	3	6	0.5	0.7		
<b>II LYMPHOMA &amp; RELATED</b>	4	22	15	38	37	79	116	11.4	12.3	2.6	1.7	2	9	9	10	39	30	69	4.6	7.4		
a. Hodgkin	0	2	2	9	21	13	34	1.8	3.3	2.2	1.1	0	1	1	4	26	6	32	0.8	3.2		
b. Non-Hodgkin except BL	0	6	7	21	12	34	46	4.7	4.7	3.1	2.2	0	1	5	5	10	11	21	1.6	2.2		
c. Burkitt (BL)	0	4	3	6	3	13	16	1.9	1.7	6.5	4.0	0	0	1	1	2	2	4	0.3	0.4		
d. Lymphoreticular	3	10	3	2	0	18	18	3.0	2.3	1.6	1.5	2	7	2	0	1	11	12	1.9	1.6		
e. Unspecified	1	0	0	0	1	1	2	0.2	0.2	-	-	0	0	0	0	0	0	0	-	-		
<b>III CNS NEOPLASMS †</b>	7	42	46	46	51	141	192	20.9	21.0	1.3	1.1	8	27	38	38	63	111	174	16.8	19.3		
a. Ependymoma	1	10	2	3	7	16	23	2.6	2.7	1.6	2.3	3	3	3	1	0	10	10	1.7	1.3		
b. Astrocytoma	5	13	20	14	13	52	65	7.8	7.2	1.3	1.2	1	13	12	15	13	41	54	6.2	6.1		
c. CNS embryonal	0	6	14	6	6	26	32	3.8	3.5	1.4	1.3	4	8	5	2	5	19	24	3.2	2.9		
d. Other gliomas	0	8	5	6	4	19	23	2.9	2.6	1.0	0.9	0	2	10	7	6	19	25	2.7	2.7		
e. Other specified	1	2	3	17	16	23	39	3.1	3.9	1.2	0.7	0	1	8	10	36	19	55	2.6	5.6		
f. Unspecified CNS	0	3	2	0	5	5	10	0.8	1.1	1.7	1.7	0	0	0	3	3	3	6	0.4	0.6		
<b>IV NEUROBLASTOMA</b>	7	14	3	0	1	24	25	4.1	3.3	0.6	0.6	16	20	2	1	1	39	40	6.9	5.5		
a. (Ganglio)neuroblastoma	7	14	3	0	0	24	24	4.1	3.2	0.6	0.6	16	20	2	1	0	39	39	6.9	5.4		
b. Peripheral nervous	0	0	0	0	1	0	1	-	0.1	-	1.0	0	0	0	0	1	0	1	-	0.1		
<b>V RETINOBLASTOMA</b>	5	4	1	0	1	10	11	1.7	1.4	0.9	1.0	3	7	1	0	0	11	11	1.9	1.5		
<b>VI RENAL TUMOURS</b>	5	15	2	0	1	22	23	3.8	3.0	0.6	0.6	3	24	5	2	4	34	38	5.9	4.9		
a. Nephroblastoma	5	15	1	0	0	21	21	3.6	2.8	0.7	0.7	3	24	4	0	1	31	32	5.5	4.3		
b. Renal carcinoma	0	0	1	0	1	1	2	0.1	0.2	0.3	0.3	0	0	1	2	3	3	6	0.4	0.6		
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
<b>VII HEPATIC TUMOURS</b>	3	11	1	2	3	17	20	2.8	2.5	1.9	2.2	3	4	2	0	0	9	9	1.6	1.2		
a. Hepatoblastoma	3	11	1	0	0	15	15	2.6	2.0	1.9	1.9	3	3	2	0	0	8	8	1.4	1.1		
b. Hepatic carcinoma	0	0	0	2	3	2	5	0.2	0.5	2.0	5.0	0	1	0	0	0	1	1	0.2	0.1		
c. Unspecified	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
<b>VIII BONE TUMOURS</b>	0	3	13	16	18	32	50	4.4	5.1	1.5	1.1	0	0	4	17	23	21	44	2.8	4.4		
a. Osteosarcoma	0	0	8	9	12	17	29	2.3	2.9	1.1	1.0	0	0	3	12	14	15	29	2.0	2.9		
b. Chondrosarcoma	0	0	1	0	1	1	2	0.1	0.2	-	2.0	0	0	0	0	1	0	1	-	0.1		
c. Ewing & related	0	3	3	7	2	13	15	1.8	1.6	3.3	1.4	0	0	1	3	7	4	11	0.5	1.1		
d. Other specified	0	0	1	0	0	1	1	0.1	0.1	1.0	0.5	0	0	0	1	1	1	2	0.1	0.2		
e. Unspecified	0	0	0	0	3	0	3	-	0.3	0.0	3.0	0	0	0	1	0	1	1	0.1	0.1		
<b>IX SOFT TISSUE SARCOMA</b>	4	16	5	11	23	36	59	5.6	6.5	1.2	1.2	2	10	7	12	17	31	48	4.7	5.4		
a. Rhabdomyosarcoma	1	11	1	4	4	17	21	2.7	2.5	1.3	1.3	0	8	2	3	3	13	16	2.1	1.9		
b. Fibrosarcoma	3	0	0	1	1	4	5	0.6	0.6	1.3	1.3	1	0	2	0	1	3	4	0.5	0.5		
c. Kaposi sarcoma	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
d. Other specified	0	4	4	5	15	13	28	1.9	2.9	1.0	1.1	1	2	2	8	12	13	25	1.9	2.6		
e. Unspecified	0	1	0	1	3	2	5	0.3	0.5	1.0	1.7	0	0	1	1	1	2	3	0.3	0.3		
<b>X GERM CELL TUMOURS</b>	2	3	2	10	48	17	65	2.4	6.3	1.1	1.9	6	2	2	6	18	16	34	2.5	3.7		
a. CNS germ cell	1	0	1	6	3	8	11	1.1	1.1	2.0	2.8	1	1	0	2	0	4	4	0.6	0.5		
b. Other extragonadal	0	0	1	0	4	1	5	0.1	0.5	0.2	0.5	4	1	1	0	5	6	11	1.0	1.3		
c. Gonadal germ cell	1	3	0	4	41	8	49	1.2	4.8	1.6	3.1	1	0	1	3	11	5	16	0.7	1.6		
d. Gonadal carcinoma	0	0	0	0	0	0	0	-	-	-	0.0	0	0	0	0	1	0	1	-	0.1		
e. Unspecified gonadal	0	0	0	0	0	0	0	-	-	0.0	0.0	0	0	0	1	1	1	2	0.1	0.2		
<b>XI CARCINOMA &amp; MELANOMA</b>	1	1	3	12	32	17	49	2.3	4.8	0.9	0.5	0	3	4	12	75	19	94	2.7	9.5		
a. Adrenocortical	1	0	0	0	0	1	1	0.2	0.1	0.3	0.3	0	3	1	0	0	4	4	0.7	0.5		
b. Thyroid	0	1	1	6	8	8	16	1.1	1.6	1.6	0.4	0	0	1	4	36	5	41	0.7	4.1		
c. Nasopharyngeal	0	0	0	2	6	2	8	0.2	0.8	2.0	2.7	0	0	0	1	2	1	3	0.1	0.3		
d. Melanoma	0	0	1	1	3	2	5	0.3	0.5	0.3	0.4	0	0	2	4	7	6	13	0.8	1.3		
e. Skin carcinoma	0	0	0	0	0	0	0	-	-	-	-	0	0	0	0	0	0	0	-	-		
f. Other & unspecified	0	0	1	3	15	4	19	0.5	1.8	1.3	0.6	0	0	0	3	30	3	33	0.4	3.3		
<b>XII OTHER &amp; UNSPECIFIED</b>	1	0	0	1	1	2	3	0.3	0.3	0.7	0.5	2	1	0	0	3	3	6	0.5	0.7		
a. Other specified	1	0	0	0	0	1	1	0.2	0.1	0.5	0.3	1	1	0	0	1	2	3	0.4	0.4		
b. Other unspecified	0	0	0	1	1	1	2	0.1	0.2	1.0	0.7	1	0	0	0	2	1	3	0.2	0.3		
<b>TOTAL</b>	55	233	147	171	277	606	883	92.8	97.8	1.2	1.1	60	181	117	141	286	499	785	78.8	89.4		

† includes 48 non-malignant in males and 56 non-malignant in females

Please consult the quality indicators for the constituent registries

## USA, NPCR, Native American (1998-2012)

	Age group	Males	Females
Person-years	0	450 078	437 402
	1-4	1 768 038	1 712 094
	5-9	2 234 320	2 167 216
	10-14	2 332 442	2 278 999
	15-19	2 408 033	2 267 138
Total	0-14	6 784 878	6 595 711
	0-19	9 192 911	8 862 849
Average annual population	0-14	452 325	439 714
	0-19	612 861	590 857

Please consult the quality indicators for the constituent registries

## USA, NPCR, Native American (1998-2012)

Registry	Period	Cases	%	Person-years	%
Alabama	1998-2012	5	0.3	138 295	0.8
Alaska	1998-2012	154	9.2	700 022	3.9
Arizona	1998-2012	249	14.9	1 941 195	10.8
Arkansas	1998-2012	8	0.5	120 551	0.7
California	1998-2012	103	6.2	3 168 323	17.5
Colorado	1998-2012	23	1.4	388 276	2.2
Delaware	1998-2012	0	0.0	23 301	0.1
District of Columbia	1998-2012	2	0.1	11 019	0.1
Florida	1998-2012	18	1.1	386 774	2.1
Georgia	1998-2012	9	0.5	197 045	1.1
Idaho	1998-2012	15	0.9	144 328	0.8
Illinois	1998-2012	11	0.7	340 728	1.9
Indiana	1998-2012	1	0.1	116 915	0.6
Kansas	1998-2012	7	0.4	196 377	1.1
Kentucky	1998-2012	2	0.1	45 098	0.2
Louisiana	1998-2012	3	0.2	162 310	0.9
Maine	1998-2012	5	0.3	47 682	0.3
Maryland	1998-2012	8	0.5	128 546	0.7
Massachusetts	1998-2012	10	0.6	142 092	0.8
Michigan	1998-2012	35	2.1	425 478	2.4
Minnesota	1998-2012	58	3.5	432 330	2.4
Mississippi	2002-2012	10	0.6	64 660	0.4
Missouri	1998-2012	5	0.3	165 987	0.9
Montana	1998-2012	70	4.2	405 895	2.2
Nebraska	1998-2012	13	0.8	140 811	0.8
Nevada	1998-2012	15	0.9	213 479	1.2
New Hampshire	1998-2012	1	0.1	19 719	0.1
New Jersey	1998-2012	6	0.4	208 976	1.2
New York State	1998-2012	24	1.4	838 487	4.6
North Carolina	1998-2012	53	3.2	674 088	3.7
North Dakota	1998-2012	42	2.5	234 062	1.3
Ohio	1998-2012	7	0.4	160 087	0.9
Oklahoma	1998-2012	345	20.7	2 050 180	11.4
Oregon	1998-2012	41	2.5	370 293	2.1
Pennsylvania	1998-2012	9	0.5	179 635	1.0
Rhode Island	1998-2012	3	0.2	49 849	0.3
South Carolina	1998-2012	2	0.1	98 597	0.5
South Dakota	2001-2012	50	3.0	401 309	2.2
Tennessee	1999-2012	7	0.4	94 691	0.5
Texas	1998-2012	60	3.6	1 083 009	6.0
Vermont	1998-2012	0	0.0	13 278	0.1
Virginia	1998-2012	4	0.2	159 528	0.9
Washington State	1998-2012	106	6.4	725 331	4.0
West Virginia	1998-2012	0	0.0	12 927	0.1
Wisconsin	1998-2012	55	3.3	348 937	1.9
Wyoming	1998-2012	14	0.8	85 260	0.5
<b>USA</b>	<b>1998-2012</b>	<b>1668</b>	<b>100.0</b>	<b>18 055 760</b>	<b>100.0</b>

Please consult the quality indicators for the constituent registries